Protocol Ledger

NCT06594991 · Phase II · RECRUITING

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Interventional Phase II clinical trial protocol NCT06594991 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-10 Enrollment: 88 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06594991
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)88 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06594991
Protocol FieldVerified Registry Value
NCT IdentifierNCT06594991
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment88 participants (ESTIMATED)
Registered Start Date2024-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI